Despite the improvement in clinical outcomes such as new chemotherapeutics or molecular targeted therapies for anaplastic lymphoma kinase or epidermal growth factor receptor, the overall survival of NSCLC still remains no significant improvements.2 So, it is urgent to develop a novel and more effective therapeutic approach to solve the dilemma. The gene discussed is ALK; the disease is non-small cell lung carcinoma.